Clinical Study
Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
Table 2
(a) MMF treatment. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patients randomized to receive either MMF or CsA treatment in the initial study phase. Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not). Patients who received 2 g MMF per day and 50% of the initial CsA dose. Patients who received the usual CsA dose Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase. Patients without a mycophenolic acid derivative at the end of the follow up phase. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(b) Mean CsA dose per day. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patients randomized to receive either MMF or CsA treatment in the initial study phase. Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not). Patients who received 2 g MMF per day and 50% of the initial CsA dose. Patients who received the usual CsA dose. Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase. Patients without a mycophenolic acid derivative at the end of the follow up phase. |